Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
| Autor: | Riely, Gregory J, Neal, Joel W, Camidge, D Ross, Spira, Alexander I, Piotrowska, Zofia, Costa, Daniel B, Tsao, Anne S, Patel, Jyoti D, Gadgeel, Shirish M, Bazhenova, Lyudmila, Zhu, Viola W, West, Howard L, Mekhail, Tarek, Gentzler, Ryan D, Nguyen, Danny, Vincent, Sylvie, Zhang, Steven, Lin, Jianchang, Bunn, Veronica, Jin, Shu, Li, Shuanglian, Jänne, Pasi A |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Lung Neoplasms Indoles Maximum Tolerated Dose Clinical Trials and Supportive Activities Oncology and Carcinogenesis Antineoplastic Agents Clinical Research Insertional 80 and over Humans Non-Small-Cell Lung Lung Aged Cancer Aniline Compounds Carcinoma Lung Cancer Evaluation of treatments and therapeutic interventions Exons Middle Aged Progression-Free Survival ErbB Receptors Pyrimidines Treatment Outcome Mutagenesis 6.1 Pharmaceuticals Female |
| Zdroj: | Cancer discovery, vol 11, iss 7 |
| Popis: | Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR gene mutations, including exon 20 insertions (EGFRex20ins), in non-small cell lung cancer, was evaluated in a phase I/II dose-escalation/expansion trial (ClinicalTrials.gov NCT02716116). Dose escalation identified 160 mg/d as the recommended phase 2 dose and maximum tolerated dose. Among 136 patients treated with 160 mg/d, the most common any-grade treatment-related adverse events (TRAE; >25%) were diarrhea (83%), nausea (43%), rash (33%), and vomiting (26%), with diarrhea (21%) the only grade ≥3 TRAE >5%. Among 28 EGFRex20ins patients treated at 160 mg/d, the investigator-assessed confirmed response rate was 43% (12/28; 95% confidence interval, 24%-63%) with median duration of response of 14 months (5.0-not reached) and median progression-free survival of 7.3 months (4.4-15.6). Mobocertinib demonstrated antitumor activity in patients with diverse EGFRex20ins variants with a safety profile consistent with other EGFR inhibitors. SIGNIFICANCE: No oral EGFR-targeted therapies are currently approved for patients with EGFRex20ins NSCLC. Mobocertinib demonstrated antitumor activity with manageable toxicity in patients with advanced EGFRex20ins NSCLC in this study, supporting additional development of mobocertinib in this patient population.See related commentary by Pacheco, p. 1617.This article is highlighted in the In This Issue feature, p. 1601. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|